Skip to main content
editorial
. 2017 May;5(Suppl 1):S14. doi: 10.21037/atm.2017.03.73

Table 1. Comparison of objective response rate and progression free survival of EGFR mutant T790M-positive patients receiving osimertinib post 1st/2nd generation TKIs across AURA trials (9-11).

Endpoint AURA 1 (n=127) AURA 2 (n=199) AURA 3 (n=279)
Objective response rate 61% 69% 71%
Median PFS 9.6 months 9.9 months 10.1 months

PFS, progression free survival; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; PFS, progression free survival.